Q
Qiang Liu
Researcher at Princess Margaret Cancer Centre
Publications - 12
Citations - 489
Qiang Liu is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Myeloid leukemia & Stem cell. The author has an hindex of 6, co-authored 12 publications receiving 364 citations. Previous affiliations of Qiang Liu include Pennsylvania State University & University of Toronto.
Papers
More filters
Journal ArticleDOI
The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor.
Jennifer C. Schroeder,Brett C. DiNatale,Iain A. Murray,Colin A. Flaveny,Qiang Liu,Elizabeth M. Laurenzana,Jyh Ming Lin,Stephen C. Strom,Curtis J. Omiecinski,Shantu Amin,Gary H. Perdew +10 more
TL;DR: Indoxyl 3-sulfate represents the first identified relatively high potency endogenous AHR ligand that plays a key role in human disease progression and may contribute to toxicity observed in kidney dialysis patients and thus represent a possible therapeutic target.
Journal ArticleDOI
Anti-cancer drug discovery and development: Bcl-2 family small molecule inhibitors.
Qiang Liu,Hong Gang Wang +1 more
TL;DR: The current status of Bcl-2 family SMIs in preclinical and clinical development is discussed, and Mcl-1-specific inhibitors are expected to be efficacious both in combination/sequential treatments and as a single agent against cancers resistant to ABT-263.
Journal ArticleDOI
Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
TL;DR: It is suggested that Atg5-dependent autophagy may contribute to the development but not chemotherapy sensitivity of murine AML induced by MLL-AF9, and was found to be involved in the survival of differentiated myeloid cells originating from MLL -AF9-driven LSCs.
Journal ArticleDOI
Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression
Kenichiro Doi,Qiang Liu,Krishne Gowda,Brian M. Barth,David F. Claxton,Shantu Amin,Thomas P. Loughran,Hong Gang Wang +7 more
TL;DR: Maritoclax belongs to a novel class of Mcl-1 inhibitors that has the potential to be developed for the treatment of AML, and was more effective than daunorubicin at inducing leukemic cell death when co-cultured with HS-5 bone marrow stroma cells, while being less toxic against HS- 5 stroma Cells.
Journal ArticleDOI
Sphingosine-1-Phosphate Receptor 3 Potentiates Inflammatory Programs in Normal and Leukemia Stem Cells to Promote Differentiation
Stephanie Z. Xie,Kerstin B. Kaufmann,Weijia Wang,Michelle Chan-Seng-Yue,Michelle Chan-Seng-Yue,Olga I. Gan,Elisa Laurenti,Elisa Laurenti,Laura García-Prat,Shin-ichiro Takayanagi,Stanley W.K. Ng,Changjiang Xu,Andy G.X. Zeng,Andy G.X. Zeng,Liqing Jin,Jessica McLeod,Elvin Wagenblast,Amanda Mitchell,James A. Kennedy,James A. Kennedy,James A. Kennedy,Qiang Liu,Héléna Boutzen,Melissa Kleinau,Joseph Jargstorf,Gareth Holmes,Yang Zhang,Veronique Voisin,Gary D. Bader,Jean C.Y. Wang,Jean C.Y. Wang,Jean C.Y. Wang,Yusuf A. Hannun,Chiara Luberto,Timm Schroeder,Mark D. Minden,John E. Dick,John E. Dick +37 more
TL;DR: It is shown that S1PR3, a receptor for the bioactive lipid sphingosine-1-phosphate, is a central regulator which drives myeloid differentiation and activates inflammatory programs in both HSC and LSC.